Poriya hospital
Tiberias, 15208, Israel
Completed
NCT Number: NCT01016210
The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET)
To explore whether recombinant LH (rLH) supplementation (Leuveris) to recombinant follicle stimulating hormone (rFSH) following GnRH antagonist treatment has an advantage in infertile women with advanced reproductive ageing undergoing IVF-ET.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
25 year–45 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 4
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- female candidate to IVF
- between 30-45 years old
Exclusion criteria
- not included for fertilization
Treatment and study plan
Leuveris
DrugIV
Primary outcomes
-
Pregnancy rate
Time frame: Starting February 2010
Secondary outcomes
-
Fertilization rate
Time frame: Starting February 2010 till April 2013
Sponsors and collaborators
Lead sponsor
The Baruch Padeh Medical Center, Poriya
Other Gov
Collaborators
- Ministry of Health, Israel
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2012
- Study completion
- 2013
- First posted
- Nov 19, 2009
- Registry last updated
- Jan 17, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.